463 related articles for article (PubMed ID: 27259241)
1. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
3. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
4. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
[TBL] [Abstract][Full Text] [Related]
5. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
7. Bronchopulmonary neuroendocrine tumors.
Gustafsson BI; Kidd M; Chan A; Malfertheiner MV; Modlin IM
Cancer; 2008 Jul; 113(1):5-21. PubMed ID: 18473355
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
Kaemmerer D; Specht E; Sänger J; Wirtz RM; Sayeg M; Schulz S; Lupp A
J Clin Endocrinol Metab; 2015 Mar; 100(3):831-40. PubMed ID: 25494861
[TBL] [Abstract][Full Text] [Related]
10. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.
Pelosi G; Rindi G; Travis WD; Papotti M
J Thorac Oncol; 2014 Mar; 9(3):273-84. PubMed ID: 24518085
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract][Full Text] [Related]
15. Comparative proteomics of pulmonary tumors with neuroendocrine differentiation.
Cho NH; Koh ES; Lee DW; Kim H; Choi YP; Cho SH; Kim DS
J Proteome Res; 2006 Mar; 5(3):643-50. PubMed ID: 16512680
[TBL] [Abstract][Full Text] [Related]
16. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.
Kaemmerer D; Reimann C; Specht E; Wirtz RM; Sayeg M; Baum RP; Schulz S; Lupp A
Oncotarget; 2015 Feb; 6(5):3346-58. PubMed ID: 25671300
[TBL] [Abstract][Full Text] [Related]
17. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors - quantitative detection of the Ki-67, TPX2, TOP2A, and hTERT telomerase subunit mRNA levels to determine proliferation activity and a potential for aggressive biological behavior.
Kalfusova A; Hilska I; Krskova L; Kalinova M; Linke Z; Kodet R
Neoplasma; 2016; 63(3):484-92. PubMed ID: 26952515
[TBL] [Abstract][Full Text] [Related]
19. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.
Makino T; Mikami T; Hata Y; Otsuka H; Koezuka S; Isobe K; Tochigi N; Shibuya K; Homma S; Iyoda A
Ann Thorac Surg; 2016 Nov; 102(5):1694-1701. PubMed ID: 27368130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
